Related references
Note: Only part of the references are listed.Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space
Manuela Joerg et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Synthesis, functional and binding profile of (R)-apomorphine based homobivalent ligands targeting the dopamine D2 receptor
Jeremy Shonberg et al.
MEDCHEMCOMM (2013)
Bivalent molecular probes for dopamine D2-like receptors
Daniela Huber et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Homobivalent Ligands of the Atypical Antipsychotic Clozapine: Design, Synthesis, and Pharmacological Evaluation
Fiona M. McRobb et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Pratibha Mehta Luthra et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2012)
Novel Bivalent Ligands for D2/D3 Dopamine Receptors: Significant Cooperative Gain in D2 Affinity and Potency
Sanjib Gogoi et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Drug therapy in patients with Parkinson's disease
Thomas Mueller
TRANSLATIONAL NEURODEGENERATION (2012)
Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors
Rishi K. Somvanshi et al.
PHARMACEUTICALS (2012)
Design Strategies for Bivalent Ligands Targeting GPCRs
Jeremy Shonberg et al.
CHEMMEDCHEM (2011)
Oligomerization of G Protein-Coupled Receptors: Biochemical and Biophysical Methods
A. A. Kaczor et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Development of a Bivalent Dopamine D2 Receptor Agonist
Julia Kuehhorn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Bivalent Dopamine D2 Receptor Ligands: Synthesis and Binding Properties
Julia Kuehhorn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Crystal structure of the β2 adrenergic receptor-Gs protein complex
Soren G. F. Rasmussen et al.
NATURE (2011)
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
Jean-Martin Beaulieu et al.
PHARMACOLOGICAL REVIEWS (2011)
Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors
Philip G. Strange
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and Its Analogues as Highly Potent Dopamine D2/D3 Agonists and as Iron Chelator: In Vivo Activity Indicates Potential Application in Symptomatic and Neuroprotective Therapy for Parkinson's Disease
Balaram Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Functionalized Congener Approach to the Design of Ligands for G Protein-Coupled Receptors (GPCRs)
Kenneth A. Jacobson
BIOCONJUGATE CHEMISTRY (2009)
1,1′-Disubstituted Ferrocenes as Molecular Hinges in Mono- and Bivalent Dopamine Receptor Ligands
Daniela Huber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Adenosine A2A Receptor-Antagonist/Dopamine D2 Receptor-Agonist Bivalent Ligands as Pharmacological Tools to Detect A2A-D2 Receptor Heteromers
Aroa Soriano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4
SP Lee et al.
BIOCHEMISTRY (2003)
Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes
Y Liang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Dopamine agonists in Parkinson's disease
R Tintner et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2003)
Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes
S Ginés et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
M Rocheville et al.
SCIENCE (2000)
Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats
C Reavill et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2000)
The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572
A Gobert et al.
NEUROPHARMACOLOGY (2000)
Share Paper
